The Freeze Drying Challenge - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Freeze Drying Challenge

Pharmaceutical Technology Europe

Diamond Sky Images/Digital Vision/Getty images
There are no two completely identical units in operation anywhere. Even if the difference is only in the version of the operating software, we are always dealing with a unique piece of equipment. Lyophilisers are also one of the few equipment items that are constantly undergoing continuous, and often significant, design changes as manufacturers respond to the evolving needs of customers. In general, there is a global shortage of freeze-drying capacity, which has led to many companies outsourcing this activity. It is not unusual for small-scale production (development to clinical phase II) to be performed at one contract manufacturer, while large-scale (clinical phase III and commercial product) manufacture takes place at another.

Siegfried Schmitt
One of the principal issues facing manufacturers is the significant differences that often occur in lyophilisation equipment performance and operation at the development and production stages. Because of this, it is difficult to develop models for process controls linking critical quality attributes with critical process parameter that scale easily, or that can be transposed from one site to another. Quality by Design (QbD) is an initiative that is gaining much attention in the industry. However, so far there isn't much proof of concept for QbD in freeze drying. In the pharmaceutical industry, there have been several QbD submissions, but lyophilisation predominantly applies to biological products and by the end of 2011 there had been no submissions that included a design space for biological compounds, according to a personal communication I had with the FDA's Lucinda Buhse in March 2012

The fact that freeze drying is mostly used for biological products also creates further challenges. Biologics tend to cost more and there are usually limited amounts of product available. Experiments with the freeze-drying process tend only to be used in early development, and even then they are performed on small scales. One key parameter that must be known is the eutectic point of the formulation, so that the melting point of the frozen product is known. Without this information, the manufacturer will not know when melt back could occur and develop a cycle that has enough safety margin to prevent melt back from occurring.

Siegfried Schmitt is Principal Consultant at PAREXEL.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology Europe,
Click here